Monitor future press releases for top-line data readouts from ONSTRIDE-1 or ONSTRIDE-2, which would represent material catalysts. This poster presentation alone does not change the investment thesis.
Price Chart
Executive Summary
Harmony Biosciences announced a poster presentation at the 17th European Narcolepsy Days featuring data from its ongoing Phase 3 trials of HBS-301, an optimized high-dose pitolisant formulation for narcolepsy (ONSTRIDE-1) and idiopathic hypersomnia (ONSTRIDE-2). This is a routine scientific conference update with no new efficacy or safety data disclosed, and no regulatory or commercial catalyst is triggered by this event.
Key Facts
- Poster presentation at European Narcolepsy Days, October 2-3, 2026 in Bern, Switzerland
- Covers Phase 3 trials ONSTRIDE-1 (narcolepsy) and ONSTRIDE-2 (idiopathic hypersomnia) of HBS-301
- HBS-301 is an investigational high-dose enteric-coated pitolisant formulation up to 60 mg
- No new data, results, or regulatory milestones were announced in the press release
Financial Impact
No financial impact disclosed; no revenue, costs, or deal terms mentioned
Risk Factors
- Phase 3 trials may fail to meet primary endpoints
- Regulatory approval for HBS-301 is not guaranteed and may face delays or rejections
- Competition from existing and pipeline narcolepsy/IH therapies could limit commercial potential
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3372860 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G/A | $36.90 | awaiting T+20 | — | $37.95 (+2.85%) |
Oct 13, 2026 14d ago | 8-K | $37.03 | awaiting T+20 | — | $37.95 (+2.48%) |
Oct 1, 2026 26d ago | Press Release | $39.57 | awaiting T+20 | — | $37.95 (−4.09%) |
Aug 4, 2026 12w ago | 8-K | $38.78 | awaiting T+20 | — | $37.95 (−2.14%) |
Aug 4, 2026 12w ago | Press Release | $38.78 | awaiting T+20 | — | $37.95 (−2.14%) |
Jul 16, 2026 14w ago | 8-K | $33.53 $38.50 | ▲ +14.82% | ▲ +11.20% | $37.95 (+13.18%) |
Jun 30, 2026 17w ago | 144 | $36.00 $35.86 | ▲ +0.39% | ▼ −1.80% | $37.95 (−5.42%) |
Jun 24, 2026 17w ago | 144 | $34.13 $35.80 | ▼ −4.89% | ▼ −4.36% | $37.95 (−11.19%) |
Jun 9, 2026 20w ago | 144 | $35.48 $38.21 | ▲ +7.69% | ▲ +4.07% | $37.95 (+6.96%) |
Jun 5, 2026 20w ago | 144 | $32.39 $37.01 | ▲ +14.26% | ▲ +12.63% | $37.95 (+17.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers